Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
暂无分享,去创建一个
K. White | M. Econs | H. Jüppner | R. Zahradnik | J. Lavigne | T. Larsson | Y. Imanishi | T. Sugimoto | K. Oba | O. Ljunggren | A. Miyauchi | H. Koshiyama | I. Yang | Takehisa Yamamoto | K. Jonsson | G. Hampson
[1] D. Miao,et al. The Autosomal Dominant Hypophosphatemic Rickets R176Q Mutation in Fibroblast Growth Factor 23 Resists Proteolytic Cleavage and Enhances in Vivo Biological Potency* , 2003, The Journal of Biological Chemistry.
[2] T. Yoneya,et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. , 2002, Endocrinology.
[3] R. Kumar,et al. Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral Metabolism , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] W. Kenn,et al. Octreotide therapy for tumor-induced osteomalacia. , 2001, The New England journal of medicine.
[5] T. Strom,et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. , 2001, Kidney international.
[6] R. Kumar,et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. , 2001, Biochemical and biophysical research communications.
[7] S. Takeda,et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] T. Spector,et al. The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate Wasting , 2001 .
[9] T. Meitinger,et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 , 2000, Nature Genetics.
[10] N. Itoh,et al. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. , 2000, Biochemical and biophysical research communications.
[11] L. Kunkel,et al. Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. , 1997, American journal of human genetics.
[12] Young Seol Kim,et al. Oncogenic Osteomalacia Caused by a Phosphaturic Mesenchymal Tumor of the Oral Cavity: A Case Report , 1997, The Korean journal of internal medicine.
[13] Brennan,et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. , 1987, Clinical chemistry.